Immutep TACTI-003 Eftilagimod Alpha Head Neck Cancer Study Results

Phase IIb clinical trial results presenting primary outcomes from Cohort B (CPS <1) evaluating soluble LAG-3 (eftilagimod alpha) combined with pembrolizumab as first-line therapy in recurrent or metastatic head and neck squamous cell carcinoma. The study investigates immunotherapy combination approach for improving patient outcomes in advanced HNSCC.